There is NO issue with the patents running out in 2018 - as Pfizer incorporated new patents into the HCV program at the time of the collaboration between Tacere Therapeutics (acquired by Benitec in October 2012) and Pfizer.
These new patents protect us/run out in 2028.
There will be an announcement to the market once the first patent is dosed as it will be a very significant moment for the company.
BLT Price at posting:
84.0¢ Sentiment: Buy Disclosure: Held